SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+24.46%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$963M
AUM Growth
+$963M
(+11%)
Cap. Flow
-$20.1M
Cap. Flow
% of AUM
-2.09%
Top 10 Holdings %
Top 10 Hldgs %
42.67%
Holding
134
New
41
Increased
18
Reduced
32
Closed
26
Top Buys
| 1 |
Eli Lilly
LLY
|
$42.9M |
| 2 |
Bristol-Myers Squibb
BMY
|
$38.8M |
| 3 |
ONCR
Oncorus, Inc.
ONCR
|
$28.4M |
| 4 |
SGTX
Sigilon Therapeutics, Inc. Common Stock
SGTX
|
$26.1M |
| 5 |
C4 Therapeutics
CCCC
|
$14.6M |
Top Sells
| 1 |
Sanofi
SNY
|
$56.2M |
| 2 |
AbbVie
ABBV
|
$48.2M |
| 3 |
Amgen
AMGN
|
$28M |
| 4 |
Amicus Therapeutics
FOLD
|
$22.6M |
| 5 |
Sarepta Therapeutics
SRPT
|
$16.5M |
Sector Composition
| 1 | Healthcare | 79.61% |
| 2 | Technology | 10.28% |
| 3 | Industrials | 3.68% |
| 4 | Consumer Discretionary | 2.21% |
| 5 | Communication Services | 1.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Zentalis Pharmaceuticals
ZNTL
$122M
| $9.91M | 0.88% | 190,796 -4,200 | -2% | -$218K |
|
|
ALXN
27
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $9.37M | 0.83% | +60,000 | New | +$9.37M |
|
|
TRIL
28
DELISTED
Trillium Therapeutics Inc.
TRIL
| $9.22M | 0.82% | 626,759 -18,676 | -3% | -$275K |
|
29
Kymera Therapeutics
KYMR
$2.95B
| $9.16M | 0.81% | 147,700 -12,300 | -8% | -$763K |
|
30
Burlington
BURL
$18.3B
| $9.15M | 0.81% | 35,000 | – | – |
|
|
TECX
31
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $9.14M | 0.81% | 655,874 +330,374 | +101% | +$4.61M |
|
32
Varonis Systems
VRNS
$6.61B
| $9.04M | 0.8% | 55,225 -5,000 | -8% | -$818K |
|
33
Immatics
IMTX
$619M
| $8.88M | 0.79% | 823,391 +23,391 | +3% | +$252K |
|
34
Camtek
CAMT
$3.78B
| $8.76M | 0.78% | +400,000 | New | +$8.76M |
|
|
IMAB
35
I-MAB
IMAB
$340M
| $8.57M | 0.76% | 181,820 | – | – |
|
36
Verint Systems
VRNT
$1.23B
| $8.53M | 0.76% | +127,000 | New | +$8.53M |
|
37
Cogent Biosciences
COGT
$1.69B
| $8.26M | 0.73% | +735,434 | New | +$8.26M |
|
38
ARS Pharmaceuticals
SPRY
$1.15B
| $8.08M | 0.72% | +174,261 | New | +$8.08M |
|
39
Teva Pharmaceuticals
TEVA
$21.1B
| $8.04M | 0.71% | 832,878 -750,000 | -47% | -$7.24M |
|
40
Immunovant
IMVT
$2.56B
| $7.85M | 0.7% | 170,000 | – | – |
|
41
uniQure
QURE
$896M
| $7.8M | 0.69% | 216,000 +90,000 | +71% | +$3.25M |
|
42
Repare Therapeutics
RPTX
$71.7M
| $7.69M | 0.68% | 224,300 -20,700 | -8% | -$710K |
|
43
Fate Therapeutics
FATE
$120M
| $7.46M | 0.66% | 82,000 -106,000 | -56% | -$9.64M |
|
44
BeyondSpring
BYSI
$69.4M
| $7.3M | 0.65% | +598,000 | New | +$7.3M |
|
|
VRNA
45
Verona Pharma
VRNA
$9.16B
| $7.24M | 0.64% | 1,033,603 +33,603 | +3% | +$235K |
|
|
BLSA
46
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $6.89M | 0.61% | +625,000 | New | +$6.89M |
|
47
Amazon
AMZN
$2.44T
| $6.71M | 0.6% | 2,061 -1,759 | -46% | -$5.73M |
|
|
MRTX
48
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $6.54M | 0.58% | 29,779 -3,221 | -10% | -$707K |
|
49
Y-mAbs Therapeutics
YMAB
$388M
| $6.49M | 0.58% | 131,016 -265,505 | -67% | -$13.1M |
|
50
Oric Pharmaceuticals
ORIC
$994M
| $6.17M | 0.55% | +182,200 | New | +$6.17M |
|